A fixed-dose combination topical medication containing a potent corticosteroid (Betamethasone dipropionate) and a vitamin D3 analogue (Calcipotriol). It is a first-line treatment for moderate to severe plaque psoriasis in adults, offering synergistic anti-inflammatory, immunosuppressive, and anti-proliferative effects. It is formulated as an ointment, cream, or gel for topical application.
Adult: Apply a thin layer once daily to the affected areas. Maximum recommended dose is 100g per week. Initial treatment period should be limited to 4 weeks. For maintenance, intermittent use (e.g., weekends-only therapy) may be employed under medical supervision.
Note: Apply to clean, dry skin. Gently rub in until absorbed. Wash hands after application unless hands are being treated. Do not use with occlusive dressings unless specifically advised by a physician. Avoid contact with eyes, mouth, and mucous membranes. Do not apply on broken or infected skin.
The combination exerts a synergistic effect on psoriasis by targeting multiple pathogenic pathways. Betamethasone provides rapid anti-inflammatory and immunosuppressive action, while Calcipotriol normalizes keratinocyte differentiation and proliferation, and has immunomodulatory effects.
Pregnancy: Category C (US FDA). Topical corticosteroids, especially potent ones, may pose a risk to the fetus if used in large amounts or for prolonged periods. Calcipotriol is absorbed systemically in small amounts. Use only if potential benefit justifies potential risk to the fetus. Avoid large surface areas, prolonged use, and occlusive dressings.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Increased risk of skin atrophy, striae, and systemic corticosteroid effects. | Major |
| Thiazide Diuretics (e.g., Hydrochlorothiazide) | Increased risk of hypercalcemia due to reduced calcium excretion. | Moderate |
| Systemic Corticosteroids (e.g., Prednisolone) | Additive risk of HPA axis suppression and Cushingoid features. | Major |
| Calcium Supplements/Vitamin D | Increased risk of hypercalcemia. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole - topical or systemic) | May inhibit metabolism of betamethasone, increasing systemic exposure and risk of side effects. | Moderate |